{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:45:00Z","timestamp":1791866700410,"version":"4.3.4"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12906-4","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:39:34Z","timestamp":1791826774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy for oral cavity tumors: recent advances, key challenges, and future perspectives"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0825-0534","authenticated-orcid":false,"given":"Gulnihol","family":"Sharipova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4227-5884","authenticated-orcid":false,"given":"Shavkat","family":"Amonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9083-5105","authenticated-orcid":false,"given":"Antonina","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5340-1372","authenticated-orcid":false,"given":"Sardor","family":"Kenjayev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasiba","family":"Masharipova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoxidxo\u2019ja","family":"Maxkamov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakhimardan","family":"Shaniyazov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5638-0786","authenticated-orcid":false,"given":"Zebiniso","family":"Alimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"2","key":"12906_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00432-025-06098-w","volume":"151","author":"J Wu","year":"2025","unstructured":"Wu J, Chen H, Liu Y, Yang R, An N (2025) The global, regional, and national burden of oral cancer, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. J Cancer Res Clin Oncol 151(2):53. https:\/\/doi.org\/10.1007\/s00432-025-06098-w","journal-title":"J Cancer Res Clin Oncol"},{"key":"12906_CR2","doi-asserted-by":"publisher","first-page":"155489","DOI":"10.1016\/j.prp.2024.155489","volume":"261","author":"D Jagadeesan","year":"2024","unstructured":"Jagadeesan D, Sathasivam KV, Fuloria NK, Balakrishnan V, Khor GH, Ravichandran M et al (2024) Comprehensive insights into oral squamous cell carcinoma: Diagnosis, pathogenesis, and therapeutic advances. Pathol - Res Pract 261:155489. https:\/\/doi.org\/10.1016\/j.prp.2024.155489","journal-title":"Pathol - Res Pract"},{"key":"12906_CR3","doi-asserted-by":"publisher","first-page":"100447","DOI":"10.1016\/j.oor.2024.100447","volume":"10","author":"N Hoda","year":"2024","unstructured":"Hoda N, Moza A, Amith KP, Sabitha KS (2024) Immunotherapy versus targeted therapy in management of recurrent squamous cell carcinoma of oral tongue. Oral Oncol Rep 10:100447. https:\/\/doi.org\/10.1016\/j.oor.2024.100447","journal-title":"Oral Oncol Rep"},{"key":"12906_CR4","doi-asserted-by":"publisher","first-page":"100683","DOI":"10.1016\/j.oor.2024.100683","volume":"12","author":"A Vishwani","year":"2024","unstructured":"Vishwani A, Varghese BT, Thomas S, Kumar A, Kaur J, Sharma A (2024) Neoadjuvant immunotherapy in advanced oral cancer: Emerging treatment paradigms. Oral Oncol Rep 12:100683. https:\/\/doi.org\/10.1016\/j.oor.2024.100683","journal-title":"Oral Oncol Rep"},{"key":"12906_CR5","doi-asserted-by":"publisher","unstructured":"Kannan N, Ramalingam K, Ramani P, Marrapodi M, Franco R, Russo D et al (2025) Immune evasion mechanisms and cutting-edge therapeutic strategies of PD-L1 pathway in oral squamous cell carcinoma: an umbrella review. Explor Immunol 5. https:\/\/doi.org\/10.37349\/ei.2025.1003228","DOI":"10.37349\/ei.2025.1003228"},{"issue":"4","key":"12906_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1515\/oncologie-2024-0086","volume":"26","author":"L Ru","year":"2024","unstructured":"Ru L, Zheng J (2024) Clinical applications and perspectives of immune checkpoint inhibitors in oral squamous cell carcinoma. Oncologie 26(4):535\u2013547. https:\/\/doi.org\/10.1515\/oncologie-2024-0086","journal-title":"Oncologie"},{"issue":"1","key":"12906_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","volume":"393","author":"R Uppaluri","year":"2025","unstructured":"Uppaluri R, Haddad Robert I, Tao Y, Le Tourneau C, Lee Nancy Y, Westra W et al (2025) Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. N Engl J Med 393(1):37\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2415434","journal-title":"N Engl J Med"},{"key":"12906_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.20517\/cdr.2025.153","volume":"8","author":"W Zhao","year":"2025","unstructured":"Zhao W, Luo Q, Yuan B, Duan H, Jiang S (2025) Unraveling resistance to immune checkpoint inhibitors in HNSCC: from mechanisms to combination therapies. Cancer Drug Resist 8:63. https:\/\/doi.org\/10.20517\/cdr.2025.153","journal-title":"Cancer Drug Resist"},{"key":"12906_CR9","doi-asserted-by":"publisher","first-page":"1485174","DOI":"10.3389\/fimmu.2024.1485174","volume":"15","author":"C Li","year":"2024","unstructured":"Li C, Dong X, Li B (2024) Tumor microenvironment in oral squamous cell carcinoma. Front Immunol 15:1485174","journal-title":"Front Immunol"},{"key":"12906_CR10","doi-asserted-by":"publisher","first-page":"100666","DOI":"10.1016\/j.oor.2024.100666","volume":"12","author":"S Babu","year":"2024","unstructured":"Babu S, Manavalan MJ, jasmine S, Krishnan M (2024) Tumor microenvironment in oral squamous cell carcinoma: Implications for novel therapies. Oral Oncol Rep 12:100666. https:\/\/doi.org\/10.1016\/j.oor.2024.100666","journal-title":"Oral Oncol Rep"},{"issue":"5","key":"12906_CR11","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s13402-025-01068-3","volume":"48","author":"N Xue","year":"2025","unstructured":"Xue N, Wang Y, Wang Z, Zeng X, Wang J, Zhang X (2025) Trends in immunotherapy for oral squamous cell carcinoma. Cell Oncol (Dordr) 48(5):1159\u20131179. https:\/\/doi.org\/10.1007\/s13402-025-01068-3","journal-title":"Cell Oncol (Dordr)"},{"key":"12906_CR12","doi-asserted-by":"publisher","unstructured":"Zhang Y, Xie J, Wu H, Huang J, Zheng D, Wang S et al (2024) NK cell based immunotherapy against oral squamous cell carcinoma. Front Immunol 15\u20132024. https:\/\/doi.org\/10.3389\/fimmu.2024.1440764","DOI":"10.3389\/fimmu.2024.1440764"},{"key":"12906_CR13","doi-asserted-by":"publisher","unstructured":"Summers SE, Salih V, Foey AD (2023) ErbB- and MUC1-targeted CAR-T cell immunotherapy of oral squamous cell carcinoma. Front Dent Med 4\u20132023. https:\/\/doi.org\/10.3389\/fdmed.2023.1116402","DOI":"10.3389\/fdmed.2023.1116402"},{"issue":"1","key":"12906_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccell.2022.10.016","volume":"41","author":"SM Norberg","year":"2023","unstructured":"Norberg SM, Hinrichs CS (2023) Engineered T cell therapy for viral and non-viral epithelial cancers. Cancer Cell 41(1):58\u201369. https:\/\/doi.org\/10.1016\/j.ccell.2022.10.016","journal-title":"Cancer Cell"},{"key":"12906_CR15","doi-asserted-by":"publisher","first-page":"104672","DOI":"10.1016\/j.critrevonc.2025.104672","volume":"209","author":"S Gupta","year":"2025","unstructured":"Gupta S, Singh A, Deorah S, Tomar A (2025) Immunotherapy in OSCC: Current trend and challenges. Crit Rev Oncol\/Hematol 209:104672. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104672","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"12","key":"12906_CR16","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.oraloncology.2011.08.007","volume":"47","author":"YA Cho","year":"2011","unstructured":"Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD (2011) Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol 47(12):1148\u20131153. https:\/\/doi.org\/10.1016\/j.oraloncology.2011.08.007","journal-title":"Oral Oncol"},{"key":"12906_CR17","doi-asserted-by":"publisher","first-page":"1703277","DOI":"10.3389\/fimmu.2025.1703277","volume":"16","author":"X Liu","year":"2025","unstructured":"Liu X, Wang D, Cheng X, Ma Y, Li S, Deng J et al (2025) Fibroblast-immune crosstalk in oral squamous cell carcinoma: from tumor promotion to immune evasion. Front Immunol 16:1703277. https:\/\/doi.org\/10.3389\/fimmu.2025.1703277","journal-title":"Front Immunol"},{"issue":"1","key":"12906_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41368-023-00249-w","volume":"15","author":"Y Tan","year":"2023","unstructured":"Tan Y, Wang Z, Xu M, Li B, Huang Z, Qin S et al (2023) Oral squamous cell carcinomas: state of the field and emerging directions. Int J Oral Sci 15(1):44. https:\/\/doi.org\/10.1038\/s41368-023-00249-w","journal-title":"Int J Oral Sci"},{"issue":"1","key":"12906_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12943-019-0983-5","volume":"18","author":"B Peltanova","year":"2019","unstructured":"Peltanova B, Raudenska M, Masarik M (2019) Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review. Mol Cancer 18(1):63. https:\/\/doi.org\/10.1186\/s12943-019-0983-5","journal-title":"Mol Cancer"},{"issue":"3","key":"12906_CR20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.4103\/jomfp.JOMFP_109_20","volume":"24","author":"N Chaudhari","year":"2020","unstructured":"Chaudhari N, Prakash N, Pradeep GL, Mahajan A, Lunawat S, Salunkhe V (2020) Evaluation of density of tumor-associated macrophages using CD163 in histological grades of oral squamous cell carcinoma, an immunohistochemical study. J Oral Maxillofac Pathol 24(3):577. https:\/\/doi.org\/10.4103\/jomfp.JOMFP_109_20","journal-title":"J Oral Maxillofac Pathol"},{"key":"12906_CR21","doi-asserted-by":"publisher","first-page":"838632","DOI":"10.1155\/2014\/838632","volume":"2014","author":"KF He","year":"2014","unstructured":"He KF, Zhang L, Huang CF, Ma SR, Wang YF, Wang WM et al (2014) CD163\u2009+\u2009tumor-associated macrophages correlated with poor prognosis and cancer stem cells in oral squamous cell carcinoma. Biomed Res Int 2014:838632. https:\/\/doi.org\/10.1155\/2014\/838632","journal-title":"Biomed Res Int"},{"key":"12906_CR22","doi-asserted-by":"publisher","unstructured":"Chohan MH, Perry M, Laurance-Young P, Salih VM, Foey AD (2023) Prognostic Role of CD68\u2009+\u2009and CD163\u2009+\u2009Tumour-Associated Macrophages and PD-L1 Expression in Oral Squamous Cell Carcinoma: A Meta-Analysis. Br J Biomed Sci 80\u20132023. https:\/\/doi.org\/10.3389\/bjbs.2023.11065","DOI":"10.3389\/bjbs.2023.11065"},{"issue":"10","key":"12906_CR23","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/j.joms.2017.03.009","volume":"75","author":"Y Yamagata","year":"2017","unstructured":"Yamagata Y, Tomioka H, Sakamoto K, Sato K, Harada H, Ikeda T et al (2017) CD163-Positive Macrophages Within the Tumor Stroma Are Associated With Lymphangiogenesis and Lymph Node Metastasis in Oral Squamous Cell Carcinoma. J Oral Maxillofac Surg 75(10):2144\u20132153. https:\/\/doi.org\/10.1016\/j.joms.2017.03.009","journal-title":"J Oral Maxillofac Surg"},{"issue":"6","key":"12906_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00262-009-0803-7","volume":"59","author":"TH Gasparoto","year":"2010","unstructured":"Gasparoto TH, de Souza Malaspina TS, Benevides L, de Melo EJ Jr., Costa MR, Damante JH et al (2010) Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment. Cancer Immunol Immunother 59(6):819\u2013828. https:\/\/doi.org\/10.1007\/s00262-009-0803-7","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"12906_CR25","doi-asserted-by":"publisher","first-page":"e103975","DOI":"10.1371\/journal.pone.0103975","volume":"9","author":"KP Lim","year":"2014","unstructured":"Lim KP, Chun NAL, Ismail SM, Abraham MT, Yusoff MN, Zain RB et al (2014) CD4\u2009+\u2009CD25hiCD127low Regulatory T Cells Are Increased in Oral Squamous Cell Carcinoma Patients. PLoS ONE 9(8):e103975. https:\/\/doi.org\/10.1371\/journal.pone.0103975","journal-title":"PLoS ONE"},{"issue":"8","key":"12906_CR26","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1600-0714.2008.00641.x","volume":"37","author":"S Schwarz","year":"2008","unstructured":"Schwarz S, Butz M, Morsczeck C, Reichert TE, Driemel O (2008) Increased number of CD25 FoxP3 regulatory T cells in oral squamous cell carcinomas detected by chromogenic immunohistochemical double staining. J Oral Pathol Med 37(8):485\u2013489. https:\/\/doi.org\/10.1111\/j.1600-0714.2008.00641.x","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"12906_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12943-024-02193-7","volume":"23","author":"M Gan","year":"2024","unstructured":"Gan M, Liu N, Li W, Chen M, Bai Z, Liu D et al (2024) Metabolic targeting of regulatory T cells in oral squamous cell carcinoma: new horizons in immunotherapy. Mol Cancer 23(1):273. https:\/\/doi.org\/10.1186\/s12943-024-02193-7","journal-title":"Mol Cancer"},{"issue":"2","key":"12906_CR28","doi-asserted-by":"publisher","first-page":"e0229089","DOI":"10.1371\/journal.pone.0229089","volume":"15","author":"X Pang","year":"2020","unstructured":"Pang X, Fan HY, Tang YL, Wang SS, Cao MX, Wang HF et al (2020) Myeloid derived suppressor cells contribute to the malignant progression of oral squamous cell carcinoma. PLoS ONE 15(2):e0229089. https:\/\/doi.org\/10.1371\/journal.pone.0229089","journal-title":"PLoS ONE"},{"issue":"1","key":"12906_CR29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5114\/aoms\/116683","volume":"19","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Wang C, Wang Y, Zhang W, Liu L, Cheng J (2023) Prognostic role of CD11b+ myeloid-derived suppressor cells in oral squamous cell carcinoma. Archives Med Sci 19(1):171\u2013179. https:\/\/doi.org\/10.5114\/aoms\/116683","journal-title":"Archives Med Sci"},{"issue":"1","key":"12906_CR30","doi-asserted-by":"publisher","first-page":"9705","DOI":"10.1038\/s41598-020-66257-6","volume":"10","author":"K Dave","year":"2020","unstructured":"Dave K, Ali A, Magalhaes M (2020) Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study. Sci Rep 10(1):9705. https:\/\/doi.org\/10.1038\/s41598-020-66257-6","journal-title":"Sci Rep"},{"issue":"2","key":"12906_CR31","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jcms.2020.12.007","volume":"49","author":"F Wehrhan","year":"2021","unstructured":"Wehrhan F, Weber M, Baran C, Agaimy A, B\u00fcttner-Herold M, Kesting M et al (2021) PD1 expression and correlation with its ligands in oral cancer specimens and peripheral blood. J Cranio-Maxillofacial Surg 49(2):118\u2013125. https:\/\/doi.org\/10.1016\/j.jcms.2020.12.007","journal-title":"J Cranio-Maxillofacial Surg"},{"issue":"1","key":"12906_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12943-025-02533-1","volume":"25","author":"Z Huang","year":"2025","unstructured":"Huang Z, Chen J, Zhu T, Li J, Ng HY, Zhou Y et al (2025) Cancer-associated fibroblasts in the tumor microenvironment: heterogeneity, crosstalk mechanisms, and therapeutic implications. Mol Cancer 25(1):19. https:\/\/doi.org\/10.1186\/s12943-025-02533-1","journal-title":"Mol Cancer"},{"issue":"1","key":"12906_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12943-023-01731-z","volume":"22","author":"L Pei","year":"2023","unstructured":"Pei L, Liu Y, Liu L, Gao S, Gao X, Feng Y et al (2023) Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer 22(1):29. https:\/\/doi.org\/10.1186\/s12943-023-01731-z","journal-title":"Mol Cancer"},{"issue":"9","key":"12906_CR34","doi-asserted-by":"publisher","first-page":"e45189","DOI":"10.7759\/cureus.45189","volume":"15","author":"N Mahapatra","year":"2023","unstructured":"Mahapatra N, Panda A, Dash K, Bhuyan L, Mishra P, Mohanty A (2023) The Study of Expression of Hypoxia-Inducible Factor-1 Alpha (HIF-1 Alpha) and Hypoxia-Inducible Factor-2 Alpha (HIF-2 Alpha) in Oral Squamous Cell Carcinoma: An Immunohistochemical Study. Cureus 15(9):e45189. https:\/\/doi.org\/10.7759\/cureus.45189","journal-title":"Cureus"},{"issue":"2","key":"12906_CR35","first-page":"605","volume":"34","author":"CC DE LIMA PO, JORGE","year":"2014","unstructured":"DE LIMA PO, JORGE CC, OLIVEIRA DT (2014) Hypoxic Condition and Prognosis in Oral Squamous Cell Carcinoma. Anticancer Res 34(2):605\u2013612","journal-title":"Anticancer Res"},{"issue":"1","key":"12906_CR36","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12957-017-1163-y","volume":"15","author":"J Zhou","year":"2017","unstructured":"Zhou J, Huang S, Wang L, Yuan X, Dong Q, Zhang D et al (2017) Clinical and prognostic significance of HIF-1\u03b1 overexpression in oral squamous cell carcinoma: a meta-analysis. World J Surg Oncol 15(1):104. https:\/\/doi.org\/10.1186\/s12957-017-1163-y","journal-title":"World J Surg Oncol"},{"issue":"1","key":"12906_CR37","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s12672-025-02150-w","volume":"16","author":"N Eghbalifard","year":"2025","unstructured":"Eghbalifard N, Nouri N, Rouzbahani S, Bakhshi M, Ghasemi Kahrizsangi N, Golafshan F et al (2025) Hypoxia signaling in cancer: HIF-1\u03b1 stimulated by COVID-19 can lead to cancer progression and chemo-resistance in oral squamous cell carcinoma (OSCC). Discover Oncol 16(1):399. https:\/\/doi.org\/10.1007\/s12672-025-02150-w","journal-title":"Discover Oncol"},{"key":"12906_CR38","doi-asserted-by":"publisher","first-page":"1412212","DOI":"10.3389\/fonc.2024.1412212","volume":"14","author":"LE Estephan","year":"2024","unstructured":"Estephan LE, Kumar G, Stewart M, Banoub R, Linnenbach A, Harshyne LA et al (2024) Altered extracellular matrix correlates with an immunosuppressive tumor microenvironment and disease progression in younger adults with oral cavity squamous cell carcinoma. Front Oncol 14:1412212. https:\/\/doi.org\/10.3389\/fonc.2024.1412212","journal-title":"Front Oncol"},{"issue":"1","key":"12906_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X et al (2023) Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer 22(1):48. https:\/\/doi.org\/10.1186\/s12943-023-01744-8","journal-title":"Mol Cancer"},{"key":"12906_CR40","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.2147\/cmar.S368738","volume":"14","author":"L Feng","year":"2022","unstructured":"Feng L, Yin K, Zhang S, Chen Z, Bao Y, Li T (2022) Anti-PD-1 Therapy is Beneficial for the Survival of Patients with Oral Squamous Cell Carcinoma. Cancer Manag Res 14:2723\u20132731. https:\/\/doi.org\/10.2147\/cmar.S368738","journal-title":"Cancer Manag Res"},{"issue":"1","key":"12906_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12935-023-02943-5","volume":"23","author":"HS Budi","year":"2023","unstructured":"Budi HS, Farhood B (2023) Targeting oral tumor microenvironment for effective therapy. Cancer Cell Int 23(1):101. https:\/\/doi.org\/10.1186\/s12935-023-02943-5","journal-title":"Cancer Cell Int"},{"key":"12906_CR42","doi-asserted-by":"publisher","unstructured":"Wu T, Tang C, Tao R, Yong X, Jiang Q, Feng C (2021) PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers. Front Immunol 12\u20132021. https:\/\/doi.org\/10.3389\/fimmu.2021.693881","DOI":"10.3389\/fimmu.2021.693881"},{"issue":"1","key":"12906_CR43","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1038\/s41598-026-38740-z","volume":"16","author":"PJ Schuler","year":"2026","unstructured":"Schuler PJ, Oliveri F, Puntigam L, Six K, Kai\u00dfer C, Maier J et al (2026) Immune checkpoint inhibition increases antigen-specific T cell response in head and neck cancer. Sci Rep 16(1):5583. https:\/\/doi.org\/10.1038\/s41598-026-38740-z","journal-title":"Sci Rep"},{"issue":"7","key":"12906_CR44","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","volume":"17","author":"TY Seiwert","year":"2016","unstructured":"Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP et al (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17(7):956\u2013965","journal-title":"Lancet Oncol"},{"issue":"19","key":"12906_CR45","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856\u20131867","journal-title":"N Engl J Med"},{"issue":"10526","key":"12906_CR46","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/s0140-6736(25)01850-1","volume":"407","author":"J Bourhis","year":"2026","unstructured":"Bourhis J, Aup\u00e9rin A, Borel C, Lefebvre G, Racadot S, Geoffrois L et al (2026) Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial. Lancet 407(10526):363\u2013374. https:\/\/doi.org\/10.1016\/s0140-6736(25)01850-1","journal-title":"Lancet"},{"issue":"10212","key":"12906_CR47","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/s0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G Jr. et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915\u20131928. https:\/\/doi.org\/10.1016\/s0140-6736(19)32591-7","journal-title":"Lancet"},{"issue":"23","key":"12906_CR48","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1200\/jco-24-01580","volume":"43","author":"DP Zandberg","year":"2025","unstructured":"Zandberg DP, Vujanovic L, Clump DA, Isett BP, Wang H, Sica G et al (2025) Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer. J Clin Oncol 43(23):2572\u20132582. https:\/\/doi.org\/10.1200\/jco-24-01580","journal-title":"J Clin Oncol"},{"issue":"4","key":"12906_CR49","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jnci\/djs629","volume":"105","author":"SC Formenti","year":"2013","unstructured":"Formenti SC, Demaria S (2013) Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 105(4):256\u2013265. https:\/\/doi.org\/10.1093\/jnci\/djs629","journal-title":"J Natl Cancer Inst"},{"key":"12906_CR50","doi-asserted-by":"publisher","unstructured":"Imamura Y, Kanno M, Fujieda S (2025) Comparative review of KEYNOTE-689 and NIVOPOSTOP trials and their impact on perioperative immunotherapy in locally advanced head and neck cancer. Cancer Treat Rev 140. https:\/\/doi.org\/10.1016\/j.ctrv.2025.103018","DOI":"10.1016\/j.ctrv.2025.103018"},{"issue":"12","key":"12906_CR51","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1200\/jco.22.00332","volume":"41","author":"RI Haddad","year":"2023","unstructured":"Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J et al (2023) Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent\/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. J Clin Oncol 41(12):2166\u20132180. https:\/\/doi.org\/10.1200\/jco.22.00332","journal-title":"J Clin Oncol"},{"issue":"10","key":"12906_CR52","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","volume":"6","author":"JD Schoenfeld","year":"2020","unstructured":"Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS et al (2020) Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol 6(10):1563\u20131570. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2955","journal-title":"JAMA Oncol"},{"issue":"4","key":"12906_CR53","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ccell.2025.02.026","volume":"43","author":"H Li","year":"2025","unstructured":"Li H, Zandberg DP, Kulkarni A, Chiosea SI, Santos PM, Isett BR et al (2025) Distinct CD8(+) T cell dynamics associate with response to neoadjuvant cancer immunotherapies. Cancer Cell 43(4):757\u201375e8. https:\/\/doi.org\/10.1016\/j.ccell.2025.02.026","journal-title":"Cancer Cell"},{"issue":"12","key":"12906_CR54","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A, Keam SJ (2019) Camrelizumab: First Global Approval. Drugs 79(12):1355\u20131361. https:\/\/doi.org\/10.1007\/s40265-019-01167-0","journal-title":"Drugs"},{"issue":"2","key":"12906_CR55","doi-asserted-by":"publisher","first-page":"101930","DOI":"10.1016\/j.xcrm.2025.101930","volume":"6","author":"HM Liu","year":"2025","unstructured":"Liu HM, Xiong XP, Yu ZL, Shao Z, Chen GL, Liu YT et al (2025) Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial. Cell Rep Med 6(2):101930. https:\/\/doi.org\/10.1016\/j.xcrm.2025.101930","journal-title":"Cell Rep Med"},{"issue":"20","key":"12906_CR56","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","volume":"330","author":"HQ Mai","year":"2023","unstructured":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J et al (2023) Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial. JAMA 330(20):1961\u20131970. https:\/\/doi.org\/10.1001\/jama.2023.20181","journal-title":"JAMA"},{"issue":"3","key":"12906_CR57","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","volume":"40","author":"ZX Wang","year":"2022","unstructured":"Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J et al (2022) Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell 40(3):277\u201388e3. https:\/\/doi.org\/10.1016\/j.ccell.2022.02.007","journal-title":"Cancer Cell"},{"issue":"6","key":"12906_CR58","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1093\/oncolo\/oyae045","volume":"29","author":"B Tang","year":"2024","unstructured":"Tang B, Duan R, Zhang X, Qin S, Wu D, Chen J et al (2024) Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma. Oncologist 29(6):e822\u2013e7. https:\/\/doi.org\/10.1093\/oncolo\/oyae045","journal-title":"Oncologist"},{"issue":"1","key":"12906_CR59","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41392-024-02087-6","volume":"9","author":"J Zhong","year":"2024","unstructured":"Zhong J, Fei K, Wu L, Li B, Wang Z, Cheng Y et al (2024) Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial. Signal Transduct Target Therapy 9(1):369. https:\/\/doi.org\/10.1038\/s41392-024-02087-6","journal-title":"Signal Transduct Target Therapy"},{"issue":"8","key":"12906_CR60","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1097\/js9.0000000000000489","volume":"109","author":"Y Huang","year":"2023","unstructured":"Huang Y, Sun J, Li J, Zhu D, Dong M, Dou S et al (2023) Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial). Int J Surg 109(8):2220\u20132227. https:\/\/doi.org\/10.1097\/js9.0000000000000489","journal-title":"Int J Surg"},{"key":"12906_CR61","doi-asserted-by":"publisher","first-page":"116203","DOI":"10.1016\/j.biopha.2024.116203","volume":"171","author":"J-W Cui","year":"2024","unstructured":"Cui J-W, Li Y, Yang Y, Yang H-K, Dong J-M, Xiao Z-H et al (2024) Tumor immunotherapy resistance: Revealing the mechanism of PD-1 \/ PD-L1-mediated tumor immune escape. Biomed Pharmacother 171:116203. https:\/\/doi.org\/10.1016\/j.biopha.2024.116203","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"12906_CR62","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s43018-022-00450-6","volume":"3","author":"LB Darragh","year":"2022","unstructured":"Darragh LB, Knitz MM, Hu J, Clambey ET, Backus J, Dumit A et al (2022) A phase I\/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. Nat Cancer 3(11):1300\u20131317. https:\/\/doi.org\/10.1038\/s43018-022-00450-6","journal-title":"Nat Cancer"},{"issue":"16suppl","key":"12906_CR63","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1200\/JCO.2023.41.16_suppl.6081","volume":"41","author":"M Bila","year":"2023","unstructured":"Bila M, Franken A, Van Dessel J, Verbandt S, Pomella V, Hatse S et al (2023) Neoadjuvant durvalumab and tremelimumab in resectable locally advanced SCC of the oral cavity: DUTRELASCO study. J Clin Oncol 41(16suppl):6081. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.6081","journal-title":"J Clin Oncol"},{"key":"12906_CR64","doi-asserted-by":"publisher","unstructured":"Pottier C, Fresnais M, Gilon M, J\u00e9rusalem G, Longuesp\u00e9e R, Sounni NE (2020) Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers (Basel) 12(3). https:\/\/doi.org\/10.3390\/cancers12030731","DOI":"10.3390\/cancers12030731"},{"key":"12906_CR65","doi-asserted-by":"crossref","unstructured":"Satgunaseelan L, Porazinski S, Strbenac D, Istadi A, Willet C, Chew T et al (2021) Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of EGFR Amplification: Implications for Novel Personalized Therapy. Front Oncol. ;Volume 11\u20132021","DOI":"10.3389\/fonc.2021.750852"},{"key":"12906_CR66","doi-asserted-by":"publisher","unstructured":"Nair S, Bonner JA, Bredel M (2022) EGFR Mutations in Head and Neck Squamous Cell Carcinoma. Int J Mol Sci 23(7). https:\/\/doi.org\/10.3390\/ijms23073818","DOI":"10.3390\/ijms23073818"},{"key":"12906_CR67","doi-asserted-by":"publisher","unstructured":"C\u00edvico-Ortega JL, Gonz\u00e1lez-Ruiz I, Ramos-Garc\u00eda P, Cruz-Granados D, Samayoa-Descamps V, Gonz\u00e1lez-Moles M (2023) Prognostic and Clinicopathological Significance of Epidermal Growth Factor Receptor (EGFR) Expression in Oral Squamous Cell Carcinoma: Systematic Review and Meta-Analysis. Int J Mol Sci 24(15). https:\/\/doi.org\/10.3390\/ijms241511888","DOI":"10.3390\/ijms241511888"},{"key":"12906_CR68","doi-asserted-by":"publisher","unstructured":"Chung CH, Saba NF, Steuer CE, Li J, Bhateja P, Johnson M et al Efficacy of concurrent cetuximab (CTX) and nivolumab (NIVO) in previously untreated recurrent and\/or metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 39(15_suppl):6017-. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.6017","DOI":"10.1200\/JCO.2021.39.15_suppl.6017"},{"issue":"6","key":"12906_CR69","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/s1470-2045(21)00136-4","volume":"22","author":"AG Sacco","year":"2021","unstructured":"Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P et al (2021) Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol 22(6):883\u2013892. https:\/\/doi.org\/10.1016\/s1470-2045(21)00136-4","journal-title":"Lancet Oncol"},{"key":"12906_CR70","doi-asserted-by":"publisher","unstructured":"Kao HF, Liao BC, Huang YL, Huang HC, Chen CN, Chen TC et al (2022) Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis. Clin Cancer Res 28(8):1560\u20131571.https:\/\/doi.org\/10.1158\/1078","DOI":"10.1158\/1078"},{"key":"12906_CR71","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2020.09.008","volume":"141","author":"Y Tao","year":"2020","unstructured":"Tao Y, Aup\u00e9rin A, Sun X, Sire C, Martin L, Coutte A et al (2020) Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH). Eur J Cancer 141:21\u201329. https:\/\/doi.org\/10.1016\/j.ejca.2020.09.008","journal-title":"Eur J Cancer"},{"key":"12906_CR72","doi-asserted-by":"publisher","unstructured":"Bhatia AK, Flamand Y, Johnson JM, Ishizuka JJ, Duan F, Tang M et al A phase II\/III trial of chemotherapy plus cetuximab versus chemotherapy plus bevacizumab versus atezolizumab plus bevacizumab following progression on immune checkpoint inhibition in recurrent\/metastatic head and neck cancers: ECOG-ACRIN EA3202. J Clin Oncol. 40(16_suppl):TPS6098\u2013TPS. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS6098","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS6098"},{"key":"12906_CR73","doi-asserted-by":"publisher","unstructured":"Fayette J, Licitra L, Harrington K, Haddad R, Siu LL, Liu YC et al (2025) INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 31(13):2617\u20132627. https:\/\/doi.org\/10.1158\/1078","DOI":"10.1158\/1078"},{"key":"12906_CR74","doi-asserted-by":"publisher","unstructured":"Nishikawa D, Suzuki H, Beppu S, Terada H, Sawabe M, Hanai N (2022) Near-Infrared Photoimmunotherapy for Oropharyngeal Cancer. Cancers (Basel) 14(22). https:\/\/doi.org\/10.3390\/cancers14225662","DOI":"10.3390\/cancers14225662"},{"issue":"10","key":"12906_CR75","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1007\/s10147-021-01960-6","volume":"26","author":"M Tahara","year":"2021","unstructured":"Tahara M, Okano S, Enokida T, Ueda Y, Fujisawa T, Shinozaki T et al (2021) A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma. Int J Clin Oncol 26(10):1812\u20131821. https:\/\/doi.org\/10.1007\/s10147-021-01960-6","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"12906_CR76","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/hed.26885","volume":"43","author":"DM Cognetti","year":"2021","unstructured":"Cognetti DM, Johnson JM, Curry JM, Kochuparambil ST, McDonald D, Mott F et al (2021) Phase 1\/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck 43(12):3875\u20133887. https:\/\/doi.org\/10.1002\/hed.26885","journal-title":"Head Neck"},{"issue":"4","key":"12906_CR77","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE (2024) The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discovery 23(4):301\u2013319. https:\/\/doi.org\/10.1038\/s41573-024-00896-6","journal-title":"Nat Rev Drug Discovery"},{"issue":"9","key":"12906_CR78","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/s41416-025-03125-y","volume":"133","author":"G Albayrak","year":"2025","unstructured":"Albayrak G, Wan PK-T, Fisher K, Seymour LW (2025) T cell engagers: expanding horizons in oncology and beyond. Br J Cancer 133(9):1241\u20131249. https:\/\/doi.org\/10.1038\/s41416-025-03125-y","journal-title":"Br J Cancer"},{"issue":"1","key":"12906_CR79","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12943-025-02390-y","volume":"24","author":"L Shui","year":"2025","unstructured":"Shui L, Wu D, Yang K, Sun C, Li Q, Yin R (2025) Bispecific antibodies: unleashing a new era in oncology treatment. Mol Cancer 24(1):212. https:\/\/doi.org\/10.1186\/s12943-025-02390-y","journal-title":"Mol Cancer"},{"key":"12906_CR80","doi-asserted-by":"publisher","first-page":"102772","DOI":"10.1016\/j.ctrv.2024.102772","volume":"128","author":"P Jim\u00e9nez-Labaig","year":"2024","unstructured":"Jim\u00e9nez-Labaig P, Rullan A, Hernando-Calvo A, Llop S, Bhide S, O\u2019Leary B et al (2024) A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies. Cancer Treat Rev 128:102772. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102772","journal-title":"Cancer Treat Rev"},{"issue":"8Supplement","key":"12906_CR81","doi-asserted-by":"publisher","first-page":"CT012","DOI":"10.1158\/1538-7445.AM2023-CT012","volume":"83","author":"EE Cohen","year":"2023","unstructured":"Cohen EE, Fayette J, Daste A, Even C, Tourneau CL, Brana I et al (2023) Abstract CT012: Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC). Cancer Res 83(8Supplement):CT012\u2013CT. https:\/\/doi.org\/10.1158\/1538-7445.AM2023-CT012","journal-title":"Cancer Res"},{"issue":"16suppl","key":"12906_CR82","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1200\/JCO.2025.43.16_suppl.6024","volume":"43","author":"CML van Herpen","year":"2025","unstructured":"van Herpen CML, Daste A, Arrazubi V, De Boer JP, Rojas KI, Clatot F et al (2025) Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of PD-L1\u2009+\u2009recurrent\/metastatic (r\/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 trial. J Clin Oncol 43(16suppl):6024. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.6024","journal-title":"J Clin Oncol"},{"key":"12906_CR83","doi-asserted-by":"publisher","first-page":"1155778","DOI":"10.3389\/fimmu.2023.1155778","volume":"14","author":"P Farhangnia","year":"2023","unstructured":"Farhangnia P, Ghomi SM, Akbarpour M, Delbandi AA (2023) Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy. Front Immunol 14:1155778. https:\/\/doi.org\/10.3389\/fimmu.2023.1155778","journal-title":"Front Immunol"},{"key":"12906_CR84","doi-asserted-by":"publisher","unstructured":"Cao F, Li Y, Fang Q, Lin R, Zhao Z, Xu P et al (2025) Cadonilimab (a PD-1\/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial. Clin Cancer Res 31(18):3876\u20133885. https:\/\/doi.org\/10.1158\/1078","DOI":"10.1158\/1078"},{"issue":"Suppl 1","key":"12906_CR85","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2147\/cpaa.S42689","volume":"5","author":"CA Portell","year":"2013","unstructured":"Portell CA, Wenzell CM, Advani AS (2013) Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol 5(Suppl 1):5\u201311. https:\/\/doi.org\/10.2147\/cpaa.S42689","journal-title":"Clin Pharmacol"},{"issue":"10","key":"12906_CR86","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","volume":"10","author":"M Herrera","year":"2024","unstructured":"Herrera M, Pretelli G, Desai J, Garralda E, Siu LL, Steiner TM et al (2024) Bispecific antibodies: advancing precision oncology. Trends Cancer 10(10):893\u2013919. https:\/\/doi.org\/10.1016\/j.trecan.2024.07.002","journal-title":"Trends Cancer"},{"key":"12906_CR87","doi-asserted-by":"publisher","first-page":"465722","DOI":"10.1016\/j.chroma.2025.465722","volume":"1744","author":"MS Karbyshev","year":"2025","unstructured":"Karbyshev MS, Kalashnikova IV, Dubrovskaya VV, Baskakova KO, Kuzmichev PK, Sandig V (2025) Trends and challenges in bispecific antibody production. J Chromatogr A 1744:465722. https:\/\/doi.org\/10.1016\/j.chroma.2025.465722","journal-title":"J Chromatogr A"},{"issue":"1","key":"12906_CR88","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41392-025-02343-3","volume":"11","author":"D Xiao","year":"2026","unstructured":"Xiao D, Zhang H, Liu Y, Li Y, Li G, Ning Y (2026) Oncolytic viruses: advanced strategies in cancer therapy. Signal Transduct Target Therapy 11(1):45. https:\/\/doi.org\/10.1038\/s41392-025-02343-3","journal-title":"Signal Transduct Target Therapy"},{"key":"12906_CR89","doi-asserted-by":"publisher","unstructured":"Harrington KJ, Kong A, Mach N, Chesney JA, Fernandez BC, Rischin D et al (2020) Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Clin Cancer Res 26(19):5153\u20135161. https:\/\/doi.org\/10.1158\/1078","DOI":"10.1158\/1078"},{"key":"12906_CR90","doi-asserted-by":"publisher","unstructured":"Mell LK, Yu YA, Brumund KT, Daniels GA, Advani SJ, Weisman RA et al Phase I trial of intravenous attenuated vaccinia virus (GL-ONC1) with concurrent chemoradiotherapy (CRT) for locoregionally advanced head and neck carcinoma. J Clin Oncol. 33(15_suppl):6026-. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.6026","DOI":"10.1200\/jco.2015.33.15_suppl.6026"},{"key":"12906_CR91","doi-asserted-by":"publisher","first-page":"107449","DOI":"10.1016\/j.jddst.2025.107449","volume":"114","author":"A Saha","year":"2025","unstructured":"Saha A, Shetty A, Dhanush Gowda AM, Manikkath A, Mathew J, Radhakrishnan R et al (2025) Advances in oncolytic viruses for the treatment of oral squamous cell carcinoma: mechanisms, therapeutic potential, and challenges. J Drug Deliv Sci Technol 114:107449. https:\/\/doi.org\/10.1016\/j.jddst.2025.107449","journal-title":"J Drug Deliv Sci Technol"},{"key":"12906_CR92","doi-asserted-by":"crossref","unstructured":"Chen L, Zuo M, Zhou Q, Wang Y (2023) Oncolytic virotherapy in cancer treatment: challenges and optimization prospects. Front Immunol. ;Volume 14\u20132023","DOI":"10.3389\/fimmu.2023.1308890"},{"issue":"1","key":"12906_CR93","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","volume":"120","author":"P Berraondo","year":"2019","unstructured":"Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, P\u00e9rez-Gracia JL et al (2019) Cytokines in clinical cancer immunotherapy. Br J Cancer 120(1):6\u201315. https:\/\/doi.org\/10.1038\/s41416-018-0328-y","journal-title":"Br J Cancer"},{"key":"12906_CR94","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.2147\/ott.S165411","volume":"11","author":"GT Wolf","year":"2018","unstructured":"Wolf GT, Moyer JS, Kaplan MJ, Newman JG, Egan JE, Berinstein NL et al (2018) IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers. Onco Targets Ther 11:3731\u20133746. https:\/\/doi.org\/10.2147\/ott.S165411","journal-title":"Onco Targets Ther"},{"key":"12906_CR95","doi-asserted-by":"publisher","first-page":"100706","DOI":"10.1016\/j.oor.2024.100706","volume":"13","author":"GT Wolf","year":"2025","unstructured":"Wolf GT, Bellile E, Mauquoi C, Nguyen A, Sartor M, Liu S et al (2025) Neoadjuvant cytokine (IRX-2) immunotherapy for resectable oral cavity carcinoma: Final results of the INSPIRE trial. Oral Oncol Rep 13:100706. https:\/\/doi.org\/10.1016\/j.oor.2024.100706","journal-title":"Oral Oncol Rep"},{"key":"12906_CR96","doi-asserted-by":"publisher","first-page":"106866","DOI":"10.1016\/j.oraloncology.2024.106866","volume":"154","author":"R Park","year":"2024","unstructured":"Park R, Li J, Slebos RJC, Chaudhary R, Poole MI, Ferraris C et al (2024) Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma. Oral Oncol 154:106866. https:\/\/doi.org\/10.1016\/j.oraloncology.2024.106866","journal-title":"Oral Oncol"},{"issue":"3","key":"12906_CR97","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","volume":"18","author":"EC Borden","year":"2019","unstructured":"Borden EC (2019) Interferons \u03b1 and \u03b2 in cancer: therapeutic opportunities from new insights. Nat Rev Drug Discov 18(3):219\u2013234. https:\/\/doi.org\/10.1038\/s41573-018-0011-2","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"12906_CR98","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.7150\/jca.19486","volume":"8","author":"H Ma","year":"2017","unstructured":"Ma H, Jin S, Yang W, Tian Z, Liu S, Wang Y et al (2017) Interferon-\u03b1 Promotes the Expression of Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma. J Cancer 8(12):2384\u20132393. https:\/\/doi.org\/10.7150\/jca.19486","journal-title":"J Cancer"},{"issue":"4","key":"12906_CR99","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/bjc.2017.442","volume":"118","author":"H Ma","year":"2018","unstructured":"Ma H, Jin S, Yang W, Zhou G, Zhao M, Fang S et al (2018) Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma. Br J Cancer 118(4):509\u2013521. https:\/\/doi.org\/10.1038\/bjc.2017.442","journal-title":"Br J Cancer"},{"issue":"3","key":"12906_CR100","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41416-018-0352-y","volume":"120","author":"H Ma","year":"2019","unstructured":"Ma H, Yang W, Zhang L, Liu S, Zhao M, Zhou G et al (2019) Interferon-alpha promotes immunosuppression through IFNAR1\/STAT1 signalling in head and neck squamous cell carcinoma. Br J Cancer 120(3):317\u2013330. https:\/\/doi.org\/10.1038\/s41416-018-0352-y","journal-title":"Br J Cancer"},{"issue":"1","key":"12906_CR101","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s10238-025-01574-6","volume":"25","author":"R Shaik","year":"2025","unstructured":"Shaik R, Royyala SA, Inapanuri B, Durgam A, Khan H, Unnisa A (2025) Tumor infiltration therapy: from FDA approval to next-generation approaches. Clin Exp Med 25(1):254. https:\/\/doi.org\/10.1007\/s10238-025-01574-6","journal-title":"Clin Exp Med"},{"key":"12906_CR102","unstructured":"Administration USFaD FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma: U.S. Food and Drug Administration 2024 [Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanoma"},{"issue":"8","key":"12906_CR103","doi-asserted-by":"publisher","first-page":"e011633","DOI":"10.1136\/jitc-2025-011633","volume":"13","author":"RL Ferris","year":"2025","unstructured":"Ferris RL, Leidner RS, Chung CH, Jimeno A, Lee SM, Sukari A et al (2025) Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma. J Immunother Cancer 13(8):e011633. https:\/\/doi.org\/10.1136\/jitc-2025-011633","journal-title":"J Immunother Cancer"},{"issue":"6","key":"12906_CR104","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00262-024-03691-9","volume":"73","author":"S Choi","year":"2024","unstructured":"Choi S, Hossain M, Lee H, Baek J, Park HS, Lim CL et al (2024) Expansion of tumor-infiltrating lymphocytes from head and neck squamous cell carcinoma to assess the potential of adoptive cell therapy. Cancer Immunol Immunother 73(6):101. https:\/\/doi.org\/10.1007\/s00262-024-03691-9","journal-title":"Cancer Immunol Immunother"},{"key":"12906_CR105","doi-asserted-by":"publisher","unstructured":"Albarr\u00e1n Fern\u00e1ndez V, Ballest\u00edn Mart\u00ednez P, Stoltenborg Granh\u00f8j J, Borch TH, Donia M, Marie Svane I (2024) Biomarkers for response to TIL therapy: a comprehensive review. J Immunother Cancer 12(3). https:\/\/doi.org\/10.1136\/jitc-2023-008640","DOI":"10.1136\/jitc-2023-008640"},{"issue":"3","key":"12906_CR106","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/1078-0432.CCR-13-3310","volume":"21","author":"TY Seiwert","year":"2015","unstructured":"Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T et al (2015) Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res 21(3):632\u2013641 10.1158\/1078\u2009\u2013\u20090432.Ccr-13-3310","journal-title":"Clin Cancer Res"},{"key":"12906_CR107","doi-asserted-by":"publisher","unstructured":"Ferris RL, Spanos WC, Leidner R, Gon\u00e7alves A, Martens UM, Kyi C et al (2021) Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J Immunother Cancer 9(6). https:\/\/doi.org\/10.1136\/jitc-2021-002568","DOI":"10.1136\/jitc-2021-002568"},{"key":"12906_CR108","doi-asserted-by":"publisher","unstructured":"Wang H-C, Chan L-P, Cho S-F (2019) Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma. Front Oncol 9\u20132019. https:\/\/doi.org\/10.3389\/fonc.2019.01084","DOI":"10.3389\/fonc.2019.01084"},{"issue":"4","key":"12906_CR109","doi-asserted-by":"publisher","first-page":"e014378","DOI":"10.1136\/jitc-2025-014378","volume":"14","author":"R Woodford","year":"2026","unstructured":"Woodford R, Demiguelarroyo MJ, Jethra R, Lorigan PC, Lim KHJ, Thistlethwaite F (2026) HosTIL territory: mapping the landscape of toxicity in TIL therapy. J Immunother Cancer 14(4):e014378. https:\/\/doi.org\/10.1136\/jitc-2025-014378","journal-title":"J Immunother Cancer"},{"key":"12906_CR110","doi-asserted-by":"publisher","first-page":"A523","DOI":"10.1136\/jitc-2021-SITC2021.492","volume":"9","author":"D O\u2019Malley","year":"2021","unstructured":"O\u2019Malley D, Lee S, Psyrri A, Sukari A, Thomas S, Wenham R et al (2021) 492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-na\u00efve patients with advanced cancers. J Immunother Cancer 9:A523\u2013A4. https:\/\/doi.org\/10.1136\/jitc-2021-SITC2021.492","journal-title":"J Immunother Cancer"},{"issue":"1","key":"12906_CR111","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s41232-025-00398-x","volume":"45","author":"E Khodabandehloo","year":"2025","unstructured":"Khodabandehloo E, Rayati M, Ahmadi E, Naghdibadi M, Moradi V, Ahmadbeigi N (2025) Harnessing the potential of gene editing technology for CAR-T cell therapy of solid tumors. Inflamm Regen 45(1):34. https:\/\/doi.org\/10.1186\/s41232-025-00398-x","journal-title":"Inflamm Regen"},{"key":"12906_CR112","doi-asserted-by":"publisher","first-page":"106329","DOI":"10.1016\/j.phrs.2022.106329","volume":"182","author":"SM Sagnella","year":"2022","unstructured":"Sagnella SM, White AL, Yeo D, Saxena P, van Zandwijk N, Rasko JEJ (2022) Locoregional delivery of CAR-T cells in the clinic. Pharmacol Res 182:106329. https:\/\/doi.org\/10.1016\/j.phrs.2022.106329","journal-title":"Pharmacol Res"},{"issue":"8","key":"12906_CR113","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","volume":"42","author":"U Uslu","year":"2024","unstructured":"Uslu U, Castelli S, June CH (2024) CAR T cell combination therapies to treat cancer. Cancer Cell 42(8):1319\u20131325. https:\/\/doi.org\/10.1016\/j.ccell.2024.07.002","journal-title":"Cancer Cell"},{"key":"12906_CR114","doi-asserted-by":"publisher","unstructured":"Perri F, Ottaviano M, Tomaciello M, De Felice F (2025) CAR-Based Cell Therapy in Head and Neck Cancer: A Comprehensive Review on Clinical Applicability. Cancers (Basel) 17(13). https:\/\/doi.org\/10.3390\/cancers17132215","DOI":"10.3390\/cancers17132215"},{"issue":"2","key":"12906_CR115","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ejh.14101","volume":"112","author":"A Mishra","year":"2024","unstructured":"Mishra A, Maiti R, Mohan P, Gupta P (2024) Antigen loss following CAR-T cell therapy: Mechanisms, implications, and potential solutions. Eur J Haematol 112(2):211\u2013222. https:\/\/doi.org\/10.1111\/ejh.14101","journal-title":"Eur J Haematol"},{"key":"12906_CR116","doi-asserted-by":"publisher","first-page":"1490911","DOI":"10.3389\/fimmu.2024.1490911","volume":"15","author":"O Nolan-Stevaux","year":"2024","unstructured":"Nolan-Stevaux O, Smith R (2024) Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies. Front Immunol 15:1490911. https:\/\/doi.org\/10.3389\/fimmu.2024.1490911","journal-title":"Front Immunol"},{"key":"12906_CR117","doi-asserted-by":"publisher","unstructured":"Papa S, Adami A, Metoudi M, Beatson R, George MS, Achkova D et al (2023) Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study. J Immunother Cancer 11(6). https:\/\/doi.org\/10.1136\/jitc-2023-007162","DOI":"10.1136\/jitc-2023-007162"},{"key":"12906_CR118","doi-asserted-by":"publisher","unstructured":"Oh D, Vu P, Baranda JC, Henry J, Rivera IIR, Eskew JD et al (2024) 50P Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies. Immuno-Oncology Technol 24. https:\/\/doi.org\/10.1016\/j.iotech.2024.100861","DOI":"10.1016\/j.iotech.2024.100861"},{"key":"12906_CR119","doi-asserted-by":"publisher","first-page":"115888","DOI":"10.1016\/j.biopha.2023.115888","volume":"169","author":"V Moradi","year":"2023","unstructured":"Moradi V, Omidkhoda A, Ahmadbeigi N (2023) The paths and challenges of off-the-shelf CAR-T cell therapy: An overview of clinical trials. Biomed Pharmacother 169:115888. https:\/\/doi.org\/10.1016\/j.biopha.2023.115888","journal-title":"Biomed Pharmacother"},{"key":"12906_CR120","doi-asserted-by":"publisher","unstructured":"Punekar SR, Ulrickson M, Specht JM, Wong DJ, Randolph Hecht J, Maus MV et al (2025) 585 DENALI-1: a seamless phase 1\/2 study of A2B395, a logic-gated, allogeneic, Tmod CAR T therapy, in patients with EGFR-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity. J Immunother Cancer 13(Suppl 2). https:\/\/doi.org\/10.1136\/jitc-2025-SITC2025.0585","DOI":"10.1136\/jitc-2025-SITC2025.0585"},{"key":"12906_CR121","doi-asserted-by":"publisher","first-page":"1511931","DOI":"10.3389\/fcell.2024.1511931","volume":"12","author":"F Dehghan","year":"2024","unstructured":"Dehghan F, Metanat Y, Askarizadeh M, Ahmadi E, Moradi V (2024) Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy. Front Cell Dev Biol 12:1511931. https:\/\/doi.org\/10.3389\/fcell.2024.1511931","journal-title":"Front Cell Dev Biol"},{"key":"12906_CR122","doi-asserted-by":"publisher","first-page":"1337557","DOI":"10.3389\/fimmu.2024.1337557","volume":"15","author":"X Lin","year":"2024","unstructured":"Lin X, Guan T, Li Y, Lin Y, Huang G, Lin Y et al (2024) Efficacy of MUC1-targeted CAR-NK cells against human tongue squamous cell carcinoma. Front Immunol 15:1337557. https:\/\/doi.org\/10.3389\/fimmu.2024.1337557","journal-title":"Front Immunol"},{"issue":"1","key":"12906_CR123","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1186\/s12885-025-13973-9","volume":"25","author":"S Liu","year":"2025","unstructured":"Liu S, Guan T, Yang F, Zhang H, Yao Y, Huang J et al (2025) Targeting CD276: a promising strategy for CAR-NK cell immunotherapy in human oral tongue squamous cell carcinoma. BMC Cancer 25(1):593. https:\/\/doi.org\/10.1186\/s12885-025-13973-9","journal-title":"BMC Cancer"},{"issue":"1","key":"12906_CR124","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/immuno5010008","volume":"5","author":"K Kaur","year":"2025","unstructured":"Kaur K, Jewett A (2025) Super-Charged Natural Killer Cells: A Promising Immunotherapeutic Strategy for Oral Cancer. Immuno 5(1):8","journal-title":"Immuno"},{"issue":"1","key":"12906_CR125","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1186\/s12967-024-05703-9","volume":"22","author":"EA Golikova","year":"2024","unstructured":"Golikova EA, Alshevskaya AA, Alrhmoun S, Sivitskaya NA, Sennikov SV (2024) TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges. J Transl Med 22(1):897. https:\/\/doi.org\/10.1186\/s12967-024-05703-9","journal-title":"J Transl Med"},{"key":"12906_CR126","doi-asserted-by":"publisher","unstructured":"Norberg S, Nagarsheth N, Sinkoe A, Adhikary S, Meyer T, Lack J et al Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers. J Clin Oncol. 38(15_suppl):101-. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.101","DOI":"10.1200\/JCO.2020.38.15_suppl.101"},{"key":"12906_CR127","doi-asserted-by":"publisher","unstructured":"Jin BY, Campbell TE, Draper LM, Stevanovi\u0107 S, Weissbrich B, Yu Z et al (2018) Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight 3(8). https:\/\/doi.org\/10.1172\/jci.insight.99488","DOI":"10.1172\/jci.insight.99488"},{"issue":"19","key":"12906_CR128","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1158\/1078-0432.CCR-14-3341","volume":"21","author":"LM Draper","year":"2015","unstructured":"Draper LM, Kwong ML, Gros A, Stevanovi\u0107 S, Tran E, Kerkar S et al (2015) Targeting of HPV-16\u2009+\u2009Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6. Clin Cancer Res 21(19):4431\u20134439 10.1158\/1078\u2009\u2013\u20090432.Ccr-14-3341","journal-title":"Clin Cancer Res"},{"issue":"1","key":"12906_CR129","doi-asserted-by":"publisher","first-page":"1929726","DOI":"10.1080\/2162402x.2021.1929726","volume":"10","author":"T Wei","year":"2021","unstructured":"Wei T, Leisegang M, Xia M, Kiyotani K, Li N, Zeng C et al (2021) Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma. Oncoimmunology 10(1):1929726. https:\/\/doi.org\/10.1080\/2162402x.2021.1929726","journal-title":"Oncoimmunology"},{"issue":"6","key":"12906_CR130","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.4049\/jimmunol.1502024","volume":"197","author":"A Kunert","year":"2016","unstructured":"Kunert A, van Brakel M, van Steenbergen-Langeveld S, da Silva M, Coulie PG, Lamers C et al (2016) MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses. J Immunol 197(6):2541\u20132552. https:\/\/doi.org\/10.4049\/jimmunol.1502024","journal-title":"J Immunol"},{"issue":"3","key":"12906_CR131","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","volume":"27","author":"NB Nagarsheth","year":"2021","unstructured":"Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, Lack JB et al (2021) TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med 27(3):419\u2013425. https:\/\/doi.org\/10.1038\/s41591-020-01225-1","journal-title":"Nat Med"},{"key":"12906_CR132","doi-asserted-by":"publisher","unstructured":"Norberg SM, Doran S, Cao J, Girda E, Haigentz M, Saraiya B et al (2025) 366 Complete tumor regression of metastatic epithelial cancer following T cell receptor (TCR)-T cell therapy. J Immunother Cancer 13(Suppl 2). https:\/\/doi.org\/10.1136\/jitc-2025-SITC2025.0366","DOI":"10.1136\/jitc-2025-SITC2025.0366"},{"issue":"6","key":"12906_CR133","doi-asserted-by":"publisher","first-page":"djv403","DOI":"10.1093\/jnci\/djv403","volume":"108","author":"X Castellsagu\u00e9","year":"2016","unstructured":"Castellsagu\u00e9 X, Alemany L, Quer M, Halec G, Quir\u00f3s B, Tous S et al (2016) HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. J Natl Cancer Inst 108(6):djv403. https:\/\/doi.org\/10.1093\/jnci\/djv403","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"12906_CR134","doi-asserted-by":"publisher","first-page":"13404","DOI":"10.1038\/s41598-019-49771-0","volume":"9","author":"J Wang","year":"2019","unstructured":"Wang J, Sun H, Zeng Q, Guo X-J, Wang H, Liu H-H et al (2019) HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. Sci Rep 9(1):13404. https:\/\/doi.org\/10.1038\/s41598-019-49771-0","journal-title":"Sci Rep"},{"issue":"1","key":"12906_CR135","doi-asserted-by":"publisher","first-page":"e965570","DOI":"10.4161\/21624011.2014.965570","volume":"4","author":"S Partlov\u00e1","year":"2015","unstructured":"Partlov\u00e1 S, Bou\u010dek J, Kloudov\u00e1 K, Luke\u0161ov\u00e1 E, Z\u00e1brodsk\u00fd M, Grega M et al (2015) Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. Oncoimmunology 4(1):e965570. https:\/\/doi.org\/10.4161\/21624011.2014.965570","journal-title":"Oncoimmunology"},{"key":"12906_CR136","doi-asserted-by":"publisher","first-page":"101899","DOI":"10.1016\/j.tranon.2024.101899","volume":"42","author":"J Zenga","year":"2024","unstructured":"Zenga J, Awan M, Frei A, Foeckler J, Kuehn R, Espinosa OV et al (2024) Tumor-specific T cells in head and neck cancer have rescuable functionality and can be identified through single-cell co-culture. Translational Oncol 42:101899. https:\/\/doi.org\/10.1016\/j.tranon.2024.101899","journal-title":"Translational Oncol"},{"issue":"8","key":"12906_CR137","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/hed.21880","volume":"34","author":"JR Montoro","year":"2012","unstructured":"Montoro JR, Mamede RC, Neder Serafini L, Saggioro FP, Figueiredo DL, Silva WA Jr. et al (2012) Expression of cancer-testis antigens MAGE-A4 and MAGE-C1 in oral squamous cell carcinoma. Head Neck 34(8):1123\u20131128. https:\/\/doi.org\/10.1002\/hed.21880","journal-title":"Head Neck"},{"issue":"9","key":"12906_CR138","doi-asserted-by":"publisher","first-page":"14719","DOI":"10.18632\/oncotarget.14830","volume":"8","author":"S Laban","year":"2017","unstructured":"Laban S, Giebel G, Kl\u00fcmper N, Schr\u00f6ck A, Doescher J, Spagnoli G et al (2017) MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. Oncotarget 8(9):14719\u201314735. https:\/\/doi.org\/10.18632\/oncotarget.14830","journal-title":"Oncotarget"},{"key":"12906_CR139","doi-asserted-by":"publisher","first-page":"102357","DOI":"10.1016\/j.tranon.2025.102357","volume":"55","author":"FJ Mulder","year":"2025","unstructured":"Mulder FJ, de Ruiter EJ, Gielgens T, Farshadpour F, de Bree R, van den Hout M et al (2025) Frequent PD-L1 expression in oral squamous cell carcinoma of non-smokers and non-drinkers, and association of tumor infiltrating lymphocytes with favorable prognosis. Transl Oncol 55:102357. https:\/\/doi.org\/10.1016\/j.tranon.2025.102357","journal-title":"Transl Oncol"},{"key":"12906_CR140","doi-asserted-by":"publisher","unstructured":"Barbari C, Fontaine T, Parajuli P, Lamichhane N, Jakubski S, Lamichhane P et al (2020) Immunotherapies and Combination Strategies for Immuno-Oncology. Int J Mol Sci 21(14). https:\/\/doi.org\/10.3390\/ijms21145009","DOI":"10.3390\/ijms21145009"},{"issue":"1","key":"12906_CR141","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M et al (2025) CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Therapy 10(1):210. https:\/\/doi.org\/10.1038\/s41392-025-02269-w","journal-title":"Signal Transduct Target Therapy"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12906-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12906-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12906-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:50:54Z","timestamp":1791863454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12906-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":141,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12906"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12906-4","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"20 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare, whether personal, professional, or financial.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical Trial Registration Number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1718"}}